437 related articles for article (PubMed ID: 34420957)
1. Functional Neurophysiological Biomarkers of Early-Stage Alzheimer's Disease: A Perspective of Network Hyperexcitability in Disease Progression.
Tok S; Ahnaou A; Drinkenburg W
J Alzheimers Dis; 2022; 88(3):809-836. PubMed ID: 34420957
[TBL] [Abstract][Full Text] [Related]
2. Network Hyperexcitability in Early-Stage Alzheimer's Disease: Evaluation of Functional Connectivity Biomarkers in a Computational Disease Model.
Stam CJ; de Haan W
J Alzheimers Dis; 2024; 99(4):1333-1348. PubMed ID: 38759000
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
4. Blood-based Aβ42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention.
Botella Lucena P; Vanherle S; Lodder C; Gutiérrez de Ravé M; Stancu IC; Lambrichts I; Vangheluwe R; Bruffaerts R; Dewachter I
Acta Neuropathol; 2022 Sep; 144(3):489-508. PubMed ID: 35796870
[TBL] [Abstract][Full Text] [Related]
5. Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer's disease.
Walsh C; Drinkenburg WH; Ahnaou A
Neurosci Biobehav Rev; 2017 Feb; 73():340-358. PubMed ID: 28027953
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
7. Neuronal Network Excitability in Alzheimer's Disease: The Puzzle of Similar versus Divergent Roles of Amyloid β and Tau.
Kazim SF; Seo JH; Bianchi R; Larson CS; Sharma A; Wong RKS; Gorbachev KY; Pereira AC
eNeuro; 2021; 8(2):. PubMed ID: 33741601
[TBL] [Abstract][Full Text] [Related]
8. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
10. Addressing the Discrepancies Between Animal Models and Human Alzheimer's Disease Pathology: Implications for Translational Research.
Polis B; Samson AO
J Alzheimers Dis; 2024; 98(4):1199-1218. PubMed ID: 38517793
[TBL] [Abstract][Full Text] [Related]
11. Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.
Ochalek A; Mihalik B; Avci HX; Chandrasekaran A; Téglási A; Bock I; Giudice ML; Táncos Z; Molnár K; László L; Nielsen JE; Holst B; Freude K; Hyttel P; Kobolák J; Dinnyés A
Alzheimers Res Ther; 2017 Dec; 9(1):90. PubMed ID: 29191219
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and morphological characterization of the AβPP/PS/tau triple transgenic mouse model and its relevance to sporadic Alzheimer's disease.
Hunter JM; Bowers WJ; Maarouf CL; Mastrangelo MA; Daugs ID; Kokjohn TA; Kalback WM; Luehrs DC; Valla J; Beach TG; Roher AE
J Alzheimers Dis; 2011; 27(2):361-76. PubMed ID: 21860086
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity.
Mullane K; Williams M
Curr Protoc Pharmacol; 2019 Mar; 84(1):e57. PubMed ID: 30802363
[TBL] [Abstract][Full Text] [Related]
14. Neurophysiological effects of human-derived pathological tau conformers in the APPKM670/671NL.PS1/L166P amyloid mouse model of Alzheimer's disease.
Tok S; Maurin H; Delay C; Crauwels D; Manyakov NV; Van Der Elst W; Moechars D; Drinkenburg WHIM
Sci Rep; 2022 May; 12(1):7784. PubMed ID: 35546164
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
Götz J; Schild A; Hoerndli F; Pennanen L
Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
Koychev I; Hofer M; Friedman N
J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
[TBL] [Abstract][Full Text] [Related]
17. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
[TBL] [Abstract][Full Text] [Related]
18. Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer's Disease.
Delgado-Peraza F; Nogueras-Ortiz CJ; Volpert O; Liu D; Goetzl EJ; Mattson MP; Greig NH; Eitan E; Kapogiannis D
Cells; 2021 Apr; 10(5):. PubMed ID: 33922642
[TBL] [Abstract][Full Text] [Related]
19. Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
Rosenberg A; Solomon A; Soininen H; Visser PJ; Blennow K; Hartmann T; Kivipelto M;
Alzheimers Res Ther; 2021 Mar; 13(1):64. PubMed ID: 33766132
[TBL] [Abstract][Full Text] [Related]
20. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
Zhang H; Lyu D; Jia J;
J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
